We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

T-Cell Redirecting Antibody

T-Cell Redirecting Antibody (TRAB) is a bispecific antibody for cancer immunotherapy, binding to tumor antigens and CD3 expressed on T cells, and redirecting these cells to neutralize tumor antigen expressing cells. Our first TRAB, ERY974, is being tested in clinical studies, and we have multiple TRAB projects in the drug discovery stage.

Reference Article:

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors

Sci Transl Med. 2017 Oct 4;9(410):eaal4291.

< Back